Zacks: Apellis Pharmaceuticals Inc (APLS) Given $32.50 Average Target Price by Analysts

Apellis Pharmaceuticals Inc (NASDAQ:APLS) has earned an average broker rating score of 1.00 (Strong Buy) from the four brokers that provide coverage for the stock, Zacks Investment Research reports. Four investment analysts have rated the stock with a strong buy rating.

Analysts have set a 12 month consensus target price of $32.50 for the company and are anticipating that the company will post ($0.27) EPS for the current quarter, according to Zacks. Zacks has also given Apellis Pharmaceuticals an industry rank of 191 out of 265 based on the ratings given to related companies.

APLS has been the topic of several research analyst reports. Citigroup initiated coverage on shares of Apellis Pharmaceuticals in a research note on Monday, December 4th. They issued a “buy” rating and a $23.00 price objective on the stock. B. Riley initiated coverage on shares of Apellis Pharmaceuticals in a research note on Thursday, February 8th. They issued a “buy” rating and a $27.00 price objective on the stock. Evercore ISI initiated coverage on shares of Apellis Pharmaceuticals in a research note on Monday, December 4th. They issued an “outperform” rating on the stock. Finally, JPMorgan Chase & Co. initiated coverage on shares of Apellis Pharmaceuticals in a research note on Monday, December 4th. They issued an “overweight” rating and a $31.00 price objective on the stock.

Several institutional investors have recently made changes to their positions in the company. Vivo Capital LLC acquired a new stake in shares of Apellis Pharmaceuticals in the fourth quarter worth $31,635,000. BlackRock Inc. acquired a new stake in Apellis Pharmaceuticals during the fourth quarter worth $21,096,000. Jennison Associates LLC acquired a new stake in Apellis Pharmaceuticals during the fourth quarter worth $13,170,000. NF Trinity Capital Hong Kong Ltd acquired a new stake in Apellis Pharmaceuticals during the fourth quarter worth $7,750,000. Finally, Candriam Luxembourg S.C.A. acquired a new stake in Apellis Pharmaceuticals during the fourth quarter worth $2,539,000. Institutional investors and hedge funds own 1.32% of the company’s stock.

Shares of Apellis Pharmaceuticals (NASDAQ APLS) traded up $0.92 during trading on Tuesday, hitting $14.93. 105,000 shares of the stock traded hands, compared to its average volume of 101,671. Apellis Pharmaceuticals has a twelve month low of $12.45 and a twelve month high of $25.49.

WARNING: “Zacks: Apellis Pharmaceuticals Inc (APLS) Given $32.50 Average Target Price by Analysts” was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.americanbankingnews.com/2018/02/13/zacks-apellis-pharmaceuticals-inc-apls-given-32-50-average-target-price-by-analysts.html.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company’s lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade.

Get a free copy of the Zacks research report on Apellis Pharmaceuticals (APLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply